CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cannasouth Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cannasouth Ltd
240 Victoria Street
Level 1, Hamilton Central
Phone: +64 79498393p:+64 79498393 Hamilton, WAI  3216  New Zealand
Placed into Administration on 3/28/2024
On 3/28/2024, Cannasouth Limited's Directors announced their decision to place the Company into Voluntary Administration. Ben Francis and Garry Whimp of Blacklock Rose Limited were appointed as the Joint Administrators of the Company.
This company is no longer actively traded on any major stock exchange.
Business Summary
Cannasouth Limited is a New Zealand-based medicinal cannabis company. The Company is a vertically integrated biopharmaceutical company dedicated to advanced product development and research. It produces cannabis-based medicines and ingredients using cannabinoid extracts from high-quality, medical-grade cultivars and holds end-to-end GMP licenses for the manufacturing of medicines including dried cannabis flower, CBD oral solutions, and pharmaceutical ingredients. It offers a suite of medicinal cannabis products, raw materials, and laboratory services for export markets, and the local medicinal cannabis markets. It provides a range of imported Cannasouth-branded medicinal cannabis products. It also offers an online clinic, and related activities, such as research and development, marketing, and sales. Its subsidiaries include Eqalis Pharmaceuticals Limited, Eqalis Innovation Limited, Cannasouth Bioscience Limited, RestoreMe Clinic Limited, Cannasouth Cultivation Limited, and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2022Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2833 Medicinal chemicals and botanical products

Subsidiaries
Business Name Address City State/Province Country
Cannasouth Plant Research NZ Ltd Waikato Innovation Park Hamilton WAI New Zealand

General Information
Outstanding Shares: 330,470,590 (As of 12/31/2023)
Stock Exchange: NZE


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, January 29, 2025